Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Julie E. Bauman,Denise J. Roe,Nabil F. Saba,Jessica Ruth Bauman,John M. Kaczmar,Barbara Burtness,Jameel Muzaffar,Ricklie Ann Julian,Steven J. Wang,Shethal Bearelly,Audrey Baker,Conor E. Steuer,Aarti Khushal Bhatia,Anshu Giri,Carlos Caulin,Laura P. Stabile,Sara M. Centuori,Christine H. Chung

Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

2020

Julie E. Bauman
Denise J. Roe
Nabil F. Saba
Jessica Ruth Bauman
John M. Kaczmar
Barbara Burtness
Jameel Muzaffar
Ricklie Ann Julian
Steven J. Wang
Shethal Bearelly
Audrey Baker
Conor E. Steuer
Aarti Khushal Bhatia
Anshu Giri
Carlos Caulin
Laura P. Stabile
Sara M. Centuori
Christine H. Chung

TPS6594Background: Patients with pan-refractory R/M HNSCC, with clinical resistance to cytotoxic therapy, anti-EGFR molecular targeting, and immunotherapy, have poor survival. An established tumor-...

Keywords:

Head and neck squamous-cell carcinoma
Phases of clinical research
Cetuximab
Oncology
Internal medicine
Ficlatuzumab
Medicine
Refractory
in patient
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations